Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Arcutis Biotherapeutics Inc. (ARQT) Insider Trading Activity
Healthcare • Biotechnology • 296 employees
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Total Value
-$3,028,852.54
Total Shares
102,455
Average Trade Value
-$77,662.89
Most Active Insider
Burnett Patrick
Total Activity: $1,266,183
Largest Single Transaction
$522,436
by Burnett Patrick on Nov 14, 2024
30-Day Activity
2 Transactions
Volume: 5,089 shares
Value: $67,603
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
See Remarks
Officer
|
Mar 4, 2025 | 954 | $12,673 | 166,089 (-0.6%) | Sale | |
|
See Remarks
Director, Officer
|
Mar 4, 2025 | 4,135 | $54,930 | 930,114 (-0.4%) | Sale | |
|
See Remarks
Director, Officer
|
Mar 3, 2025 | 20,880 | $272,089 | 934,249 (-2.2%) | Sale | |
|
Director
|
Mar 3, 2025 | 10,000 | $130,048 | 131,944 (-7.6%) | Sale | |
|
See Remarks
Officer
|
Mar 3, 2025 | 3,263 | $42,520 | 209,429 (-1.6%) | Sale | |
|
See Remarks
Officer
|
Mar 3, 2025 | 2,819 | $36,735 | 167,043 (-1.7%) | Sale | |
|
Chief Financial Officer
Officer
|
Feb 28, 2025 | 34,000 | $0 | 192,374 (+17.7%) | Grant | |
|
See Remarks
Officer
|
Feb 28, 2025 | 38,000 | $0 | 152,862 (+24.9%) | Grant | |
|
See Remarks
Director, Officer
|
Feb 28, 2025 | 151,000 | $0 | 955,129 (+15.8%) | Grant | |
|
See Remarks
Officer
|
Feb 28, 2025 | 34,000 | $0 | 212,692 (+16.0%) | Grant | |
|
See Remarks
Officer
|
Feb 28, 2025 | 17,000 | $0 | 190,555 (+8.9%) | Grant | |
|
See Remarks
Officer
|
Feb 28, 2025 | 38,000 | $0 | 173,555 (+21.9%) | Grant | |
|
See Remarks
Officer
|
Feb 28, 2025 | 17,000 | $0 | 169,862 (+10.0%) | Grant | |
|
See Remarks
Officer
|
Feb 3, 2025 | 8,338 | $105,893 | 178,692 (-4.7%) | Sale | |
|
See Remarks
Director, Officer
|
Feb 3, 2025 | 19,301 | $245,123 | 804,129 (-2.4%) | Sale | |
|
Director
|
Feb 3, 2025 | 10,000 | $127,100 | 141,944 (-7.0%) | Sale | |
|
See Remarks
Officer
|
Feb 3, 2025 | 12,116 | $153,873 | 114,862 (-10.5%) | Sale | |
|
See Remarks
Officer
|
Feb 3, 2025 | 2,173 | $27,597 | 135,555 (-1.6%) | Sale | |
|
Director
|
Jan 2, 2025 | 10,000 | $146,714 | 151,944 (-6.6%) | Sale | |
|
See Remarks
Officer
|
Dec 31, 2024 | 1,691 | $23,674 | 126,978 (-1.3%) | Sale | |
|
See Remarks
Director, Officer
|
Dec 20, 2024 | 15,000 | $227,567 | 823,430 (-1.8%) | Sale | |
|
Director
|
Dec 2, 2024 | 10,000 | $125,133 | 161,944 (-6.2%) | Sale | |
|
See Remarks
Officer
|
Nov 30, 2024 | 1,657 | $11,775 | 187,030 (+0.9%) | Purchase | |
|
See Remarks
Director, Officer
|
Nov 30, 2024 | 2,038 | $14,482 | 838,430 (+0.2%) | Purchase | |
|
See Remarks
Officer
|
Nov 30, 2024 | 1,093 | $7,767 | 137,728 (+0.8%) | Purchase | |
|
See Remarks
Officer
|
Nov 22, 2024 | 16,023 | $162,515 | 128,669 (-12.5%) | Sale | |
|
See Remarks
Officer
|
Nov 22, 2024 | 16,023 | $10,000 | 144,692 (+11.1%) | Exercise/Conversion | |
|
See Remarks
Officer
|
Nov 19, 2024 | 1,775 | $17,190 | 181,373 (-1.0%) | Sale | |
|
See Remarks
Officer
|
Nov 18, 2024 | 4,875 | $10,000 | 183,148 (+2.7%) | Grant | |
|
See Remarks
Officer
|
Nov 15, 2024 | 100 | $1,003 | 128,669 (-0.1%) | Sale | |
|
See Remarks
Officer
|
Nov 15, 2024 | 100 | $10,000 | 128,769 (+0.1%) | Exercise/Conversion | |
|
See Remarks
Officer
|
Nov 14, 2024 | 18,377 | $10,000 | 147,046 (+12.5%) | Exercise/Conversion | |
|
See Remarks
Officer
|
Nov 14, 2024 | 18,377 | $189,182 | 128,669 (-14.3%) | Sale | |
|
See Remarks
Officer
|
Nov 14, 2024 | 50,749 | $522,436 | 128,669 (-39.4%) | Sale | |
|
Director
|
Nov 11, 2024 | 8,687 | $94,238 | 10,139 (-85.7%) | Sale | |
|
See Remarks
Officer
|
Nov 4, 2024 | 5,015 | $43,551 | 178,273 (-2.8%) | Sale | |
|
See Remarks
Officer
|
Nov 4, 2024 | 15,441 | $134,093 | 179,418 (-8.6%) | Sale | |
|
See Remarks
Director, Officer
|
Nov 4, 2024 | 13,871 | $120,459 | 832,392 (-1.7%) | Sale | |
|
Director
|
Nov 1, 2024 | 10,000 | $86,541 | 171,944 (-5.8%) | Sale |